Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022

“Phosphatidylinositol 3 kinase delta inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in “Phosphatidylinositol 3 kinase delta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

“Phosphatidylinositol 3 kinase delta inhibitors Understanding

“Phosphatidylinositol 3 kinase delta inhibitors: Overview

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression. These anti-cancer drugs are examples of targeted therapy.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence “Phosphatidylinositol 3 kinase delta inhibitors R&D. The therapies under development are focused on novel approaches for “Phosphatidylinositol 3 kinase delta inhibitors.

“Phosphatidylinositol 3 kinase delta inhibitors Emerging Drugs Chapters

This segment of the “Phosphatidylinositol 3 kinase delta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

“Phosphatidylinositol 3 kinase delta inhibitors Emerging Drugs
• Umbralisib: TG Therapeutics

Umbralisib (TGR-1202) is an oral inhibitor of PI3K-delta and CK1-epsilon administered once daily. Umbralisib is presently being evaluated in patients with Non-Hodgkin's lymphoma (NHL) and Chronic lymphocytic leukaemia (CLL) in combination with other agents including ublituximab. The phosphoinositide-3-kinases (PI3Ks) are a family of enzymes involved in many important cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity.
• Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). It is currently under evaluation as a monotherapy in several ongoing Phase 2 trials as a treatment for non-Hodgkin lymphomas (follicular, marginal zone and mantle cell); and autoimmune hemolytic anemia. Pivotal trials of parsaclisib in combination with ruxolitinib for the treatment of patients with myelofibrosis are underway; and there are plans to initiate a trial to evaluate parsaclisib in combination with tafasitamab for B-cell malignancies. In December 2018, Innovent and Incyte entered into a strategic collaboration for three clinical-stage product candidates, including parsaclisib. Under the terms of the agreement, Innovent has received the rights to develop and commercialize parsaclisib and two other assets in Mainland China, Hong Kong, Macau and Taiwan.

Further product details are provided in the report……..

“Phosphatidylinositol 3 kinase delta inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different “Phosphatidylinositol 3 kinase delta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on “Phosphatidylinositol 3 kinase delta inhibitors

There are approx. 20+ key companies which are developing the “Phosphatidylinositol 3 kinase delta inhibitors. The companies which have their “Phosphatidylinositol 3 kinase delta inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, TG Therapeutics.
• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

“Phosphatidylinositol 3 kinase delta inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

“Phosphatidylinositol 3 kinase delta inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses “Phosphatidylinositol 3 kinase delta inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging “Phosphatidylinositol 3 kinase delta inhibitors drugs.

“Phosphatidylinositol 3 kinase delta inhibitors Report Insights
• “Phosphatidylinositol 3 kinase delta inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

“Phosphatidylinositol 3 kinase delta inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing “Phosphatidylinositol 3 kinase delta inhibitors drugs?
• How many “Phosphatidylinositol 3 kinase delta inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of “Phosphatidylinositol 3 kinase delta inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the “Phosphatidylinositol 3 kinase delta inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for “Phosphatidylinositol 3 kinase delta inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• TG Therapeutics
• Incyte Corporation
• Nanjing Zenshine Pharmaceuticals
• Shanghai Yingli Pharmaceutical
• Bayer HealthCare Pharmaceuticals
• Novartis
• Rhizen Pharmaceuticals
• Secura Bio
• Applied Therapeutics
• Hillstream BioPharma
• Celon pharma
• Yuhan
• Gilead Sciences
• Chia Tai Tianqing Pharmaceutical Group
• Acerta Pharma
• BR 101801
• BeiGene
• Nanjing Sanhome Pharmaceutical
• Hutchison MediPharma
• Calistoga Pharmaceuticals
• Kyowa Kirin

Key Products
• Umbralisib
• Parsaclisib
• Zandelisib
• ZX 101A
• Linperlisib
• CAL-101
• SHC 014748M
• HMPL-689
• BGB-10188
• BR 101801
• ACP 319
• Copanlisib
• TQ B3525
• Leniolisib
• GS-9820
• Tenalisib
• YH 25248
• Duvelisib
• HSB-501
• AT-104